Browse by Poster Presenter

Schedule at a Glance

Icon Legend

This session is not in your schedule.

This session is in your schedule. Click again to remove it.

Browse by Poster Presenter

Type here to filter the list

R
Rabideau, Cathleen

University of Florida
(P 248) AN EX VIVO ASSAY TO PREDICT IMMUNOTHERAPY RESPONSE IN SARCOMA
Cathleen Rabideau
Favorite
Rabino, Martina

University Hospital S. Luigi Gonzaga
(P 231) INCREASED LIFETIME RISK (LTR) OF SOFT TISSUE SARCOMAS (STS) IN PATIENTS WITH LOW-RISK GASTROINTESTINAL STROMAL TUMORS (GIST): A RETROSPECTIVE ANALYSIS FROM THE ITALIAN SARCOMA GROUP (ISG)
Martina Rabino
Favorite
Radaelli, Stefano

Fondazione IRCCS Istituto Nazionale dei Tumori
(P 308) IMPACT OF PSOAS MUSCLE RESECTION ON OUTCOMES IN PRIMARY RETROPERITONEAL DEDIFFERENTIATED LIPOSARCOMA
Stefano Radaelli
Favorite
Ragbir, Maniram

The Newcastle upon Tyne Hospitals NHS Foundation Trust
(P 314) AN INTERNATIONAL, MULTI-CENTRE STUDY OF SURGICAL MARGINS IN INTERMEDIATE TO HIGH GRADE SARCOMA
Maniram Ragbir
Favorite
Rai, Kunal

MD Anderson Cancer Center
(P 47) EWSR1::WT1 FUSION ONCOPROTEIN ACTIVITY SHAPES LINEAGE HETEROGENEITY IN DESMOPLASTIC SMALL ROUND CELL TUMORS
Kunal Rai
Favorite
(P 391) ATRX LOSS BLOCKS THE DIFFERENTIATION OF MESENCHYMAL STEM CELLS AND ADVANCES UNDIFFERENTIATED SARCOMA DEVELOPMENT
Kunal Rai
Favorite
Rainusso, Nino

Texas Children's Hospital
(P 08) BUILDING A MEDICAL DONATION NETWORK TO ENHANCE DEVELOPMENT OF PEDIATRIC TUMOR MODELS
Nino Rainusso
Favorite
RAJA, ANAND

Cancer Institute (WIA), Adyar, Chennai
(P 110) DEFINITIVE RADIATION THERAPY IN "OPERABLE" EWING SARCOMA OF THE EXTREMITIES AND PELVIS
ANAND RAJA
Favorite
Rajamanickam, Venkatesh

Providence Cancer Institute
(P 58) PLK1 AS A VULNERABLE TARGET OF BAP1-DRIVEN UNDIFFERENTIATED PLEOMORPHIC SARCOMAS
Venkatesh Rajamanickam
Favorite
Raj, Aneesha

University of Miami
(P 333) METABOLIC SYNDROME CORRELATION WITH LIPOSARCOMA INCIDENCE AND OUTCOMES: A RETROSPECTIVE ANALYSIS.
Aneesha Raj
Favorite
Rajani, Rajiv

Texas Tech University Health Science Center El Paso
(P 78) MENTAL HEALTH DISORDERS FOLLOWING PATHOLOGICAL FRACTURE: A RETROSPECTIVE COHORT STUDY
Rajiv Rajani
Favorite
Raj, Reeja

MD Anderson Cancer Center
(P 351) THE ROLE OF SOCIOECONOMIC DISPARITIES ON SURVIVAL OUTCOMES IN MALIGNANT PERIPHERAL NERVE SHEATH TUMORS
Reeja Raj
Favorite
Raj, Reeja

The University of Texas MD Anderson Cancer Center
(P 460) OUTCOMES OF LATER-LINES SYSTEMIC THERAPIES IN MALIGNANT PERIPHERAL NERVE SHEATH TUMORS (MPNST)
Reeja Raj
Favorite
Ramadwar, Mukta

Tata Memorial Hospital
(P 286) INTERSTITIAL BRACHYTHERAPY FOR ORGAN AND FUNCTION PRESERVATION IN SOFT TISSUE SARCOMAS: LONG TERM OUTCOMES
Mukta Ramadwar
Favorite
(P 292) CRANIOVERTEBRAL EWINGS SARCOMA WITH MENINGEAL INFILTRATION - A CLINICAL OUTCOME ANALYSIS
Mukta Ramadwar
Favorite
(P 338) POORLY DIFFERENTIATED SYNOVIAL SARCOMA: A HISTOLOGIC CHALLENGE OF AN AGGRESSIVE VARIANT
Mukta Ramadwar
Favorite
(P 379) IMPACT OF EWSR1 GENE REARRANGEMENT TESTING ON DIAGNOSIS OF A WIDE RANGE OF SOLID TUMOURS
Mukta Ramadwar
Favorite
(P 387) TREATMENT PATTERNS AND PROGNOSTIC FACTORS IN LOCALISED SYNOVIAL SARCOMA: A RETROSPECTIVE STUDY FROM A TERTIARY CANCER CENTRE IN INDIA
Mukta Ramadwar
Favorite
(P 438) RANDOMIZED, OPEN-LABEL, PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY VERSUS OBSERVATION IN NON-METASTATIC, HIGH-RISK SOFT TISSUE SARCOMAS (ACO-SARC TRIAL)
Mukta Ramadwar
Favorite
Ramakrishnan, Subhash

Childrens Oncology Group
(P 168) LEVERAGING LARGE LANGUAGE MODELS FOR STRUCTURED INFORMATION EXTRACTION FROM EWING SARCOMA PATHOLOGY REPORTS
Subhash Ramakrishnan
Favorite
Ramírez de Olano, Amaya

Hospital Santa Creu i Sant Pau
(P 218) THE IMPACT OF BROADENED GENETIC COUNSELLING REFERRAL CRITERIA IN SARCOMA PATIENTS: A REFERENCE CENTRE'S EXPERIENCE
Amaya Ramírez de Olano
Favorite
Ramon y Cajal Asensio, Teresa

Hospital Clínic, Barcelona
(P 218) THE IMPACT OF BROADENED GENETIC COUNSELLING REFERRAL CRITERIA IN SARCOMA PATIENTS: A REFERENCE CENTRE'S EXPERIENCE
Teresa Ramon y Cajal Asensio
Favorite
Ramos, Jorge D.

Parabilis Medicines
(P 415) A PHASE 1/2 TRIAL OF FOG-001, A FIRST-IN-CLASS DIRECT β-CATENIN:TCF4 INHIBITOR: SAFETY AND PRELIMINARY ANTITUMOR ACTIVITY IN PATIENTS WITH DESMOID TUMORS (DT)
Jorge D. Ramos
Favorite
Ramsey, Duncan

Oregon Health & Science University
(P 93) INTERCALARY COMPRESSIVE OSSEOINTEGRATION OF DIAPHYSEAL TUMORS: A MULTI-INSTITUTIONAL CASE SERIES
Duncan Ramsey
Favorite
(P 364) TRENDS IN SURGICAL MANAGEMENT OF DESMOID TUMOR IN THE VETERANS AFFAIRS (VA) NATIONAL DATABASE
Duncan Ramsey
Favorite
Rana, Chahat

University of Texas Southwestern Medical Center
(P 03) CONGRUENCE OF CIRCULATING TUMOR DNA & RADIOGRAPHIC RESPONSE IN BONE AND SOFT TISSUE SARCOMA
Chahat Rana
Favorite
Randall, Lor

University of California Davis School of Medicine
(P 77) BARRIERS TO GUIDELINE CONCORDANT CARE IN AYA PATIENTS WITH BONE SARCOMAS
Lor Randall
Favorite
Randall, R. Lor

UC Davis Health
(P 95) COMPARATIVE OUTCOMES OF OPERATIVE AND NON-OPERATIVE TREATMENT FOR METASTATIC HUMERAL PATHOLOGIC FRACTURES
R. Lor Randall
Favorite
(P 106) REPAIR: A PRELIMINARY REPORT ON AN ONGOING MULTI-CENTER TRIAL FOR PATIENTS UNDERGOING SURGICAL STABILIZATION FOR METASTATIC BONE DISEASE OF THE FEMUR
R. Lor Randall
Favorite
(P 349) THE COST OF SURVEILLANCE IN CALIFORNIA: MRI UTILIZATION IN RECURRENT EXTREMITY SOFT TISSUE SARCOMA
R. Lor Randall
Favorite
(P 360) MRI SURVEILLANCE PRACTICES AND RECURRENCE DETECTION IN EXTREMITY SOFT TISSUE SARCOMA: A RETROSPECTIVE STUDY
R. Lor Randall
Favorite
Ranger, Ann

SOTIO Biotech Inc.
(P 257) TARGETING LEUCINE-RICH REPEAT-CONTAINING PROTEIN 15 (LRRC15): SOT106 ANTIBODY-DRUG CONJUGATE FOR SOFT TISSUE SARCOMA AND OSTEOSARCOMA TREATMENT
Ann Ranger
Favorite
Ranjbarian, Tannaz

University of California San Diego
(P 179) NEOADJUVANT AVAPRITINIB IN PDGFRA-MUTANT GIST: NEAR COMPLETE PATHOLOGICAL RESPONSES AT THE COST OF HIGH ADVERSE EVENT RATES
Tannaz Ranjbarian
Favorite
(P 180) COMPARATIVE EFFICACY OF GENERIC AND BRAND-NAME IMATINIB IN NEOADJUVANT TREATMENT OF KIT EXON 11 MUTANT GIST
Tannaz Ranjbarian
Favorite
Rankin, Kenneth

The Newcastle upon Tyne Hospitals NHS Foundation Trust, United Kingdom
(P 133) INVESTIGATION OF COMBINING MDM2 INHIBITORS WITH DR5 AGONISTS FOR BONE SARCOMA TREATMENT
Kenneth Rankin
Favorite
(P 135) EXPLORING THE ROLE OF CLUSTER OF DIFFERENTIATION 44 IN CHONDROSARCOMA
Kenneth Rankin
Favorite
Rankin, Kenneth

The Newcastle upon Tyne Hospitals NHS Foundation Trust
(P 314) AN INTERNATIONAL, MULTI-CENTRE STUDY OF SURGICAL MARGINS IN INTERMEDIATE TO HIGH GRADE SARCOMA
Kenneth Rankin
Favorite
Raskin, Kevin

MGH, Harvard
(P 105) TREATMENT SUCCESS RATE AFTER SURGICAL MANAGEMENT OF PERIPROSTHETIC JOINT INFECTIONS IN ONCOLOGIC PROXIMAL TIBIA RECONSTRUCTION
Kevin Raskin
Favorite
Raso, Jon

Moffitt Cancer Center
(P 102) FACTORS RELATED TO ASEPTIC LOOSENING IN ENDOPROSTHESIS RECONSTRUCTION OF THE PROXIMAL TIBIA
Jon Raso
Favorite
Rasool, Ghulam

Moffitt Cancer Center
(P 138) A MULTI-INSTITUTIONAL ARCHIVE AND DEEP LEARNING PIPELINE FOR QUANTIFYING CHONDROSARCOMA COMPOSITION
Ghulam Rasool
Favorite
RASTOGI, SAMEER

All India Institute Of Medical Sciences
(P 276) RADIATION-INDUCED SARCOMA (RIS): CLINICAL SPECTRUM AND ONCOLOGIC OUTCOMES FROM A TERTIARY INDIAN SARCOMA CLINIC
SAMEER RASTOGI
Favorite
(P 435) A PHASE II STUDY OF HIGH DOSE IFOSFAMIDE IN METASTATIC/LOCALLY ADVANCED SYNOVIAL SARCOMA FROM A TERTIARY CARE CENTER IN INDIA
SAMEER RASTOGI
Favorite
(P 468) CLINICAL UTILITY OF TARGETED NEXT-GENERATION SEQUENCING IN GUIDING SARCOMA DIAGNOSIS AND PERSONALIZED MANAGEMENT: A SINGLE-CENTER STUDY FROM INDIA
SAMEER RASTOGI
Favorite
Rastrelli, Marco

Veneto Institute of Oncology IOV-IRCCS
(P 328) INNOVATING SARCOMA EDUCATION: EARLY OUTCOMES OF THE ITALIAN SOCIETY OF SURGICAL ONCOLOGY (SICO) SARCOMA SOCIAL MULTI-PLATFORM JOURNAL CLUB INITIATIVE
Marco Rastrelli
Favorite
Ratan, Ravin

University of Texas MD Anderson Cancer Center
(P 47) EWSR1::WT1 FUSION ONCOPROTEIN ACTIVITY SHAPES LINEAGE HETEROGENEITY IN DESMOPLASTIC SMALL ROUND CELL TUMORS
Ravin Ratan
Favorite
(P 83) OUTCOMES OF MULTIMODAL PERIOPERATIVE TREATMENT IN OSTEOSARCOMAS OF THE JAW
Ravin Ratan
Favorite
(P 242) IMMUNE PROFILING OF UNDIFFERENTIATED PLEOMORPHIC SARCOMAS REVEALS DISTINCT PROGNOSTIC SUBGROUPS
Ravin Ratan
Favorite
(P 315) ANALYSIS OF CHANGES IN T2-WEIGHTED SIGNAL INTENSITY AND TUMOR VOLUME AND EXPOSURE-RESPONSE IN THE RINGSIDE PHASE 2 STUDY OF VAREGACESTAT FOR DESMOID TUMORS
Ravin Ratan
Favorite
(P 410) SUBGROUP ANALYSIS OF THE PHASE 2 PART OF THE RINGSIDE PHASE 2/3 TRIAL OF VAREGACESTAT FOR TREATMENT OF DESMOID TUMORS
Ravin Ratan
Favorite
(P 416) A PHASE 2 MULTICENTER OPEN-LABEL BASKET STUDY OF TAZEMETOSTAT IN ADULT PATIENTS WITH INI1-NEGATIVE EPITHELIOID SARCOMA – FINAL ANALYSIS
Ravin Ratan
Favorite
(P 451) TREATMENT OUTCOMES OF GEMCITABINE AND DOCETAXEL IN PATIENTS WITH CLEAR CELL SARCOMA (CCS) OR GASTROINTESTINAL NEUROECTODERMAL TUMOR (GNET): A CASE SERIES
Ravin Ratan
Favorite
(P 460) OUTCOMES OF LATER-LINES SYSTEMIC THERAPIES IN MALIGNANT PERIPHERAL NERVE SHEATH TUMORS (MPNST)
Ravin Ratan
Favorite
Rath, Sushmita

TATA MEMORIAL HOSPITAL
(P 286) INTERSTITIAL BRACHYTHERAPY FOR ORGAN AND FUNCTION PRESERVATION IN SOFT TISSUE SARCOMAS: LONG TERM OUTCOMES
Sushmita Rath
Favorite
(P 292) CRANIOVERTEBRAL EWINGS SARCOMA WITH MENINGEAL INFILTRATION - A CLINICAL OUTCOME ANALYSIS
Sushmita Rath
Favorite
(P 387) TREATMENT PATTERNS AND PROGNOSTIC FACTORS IN LOCALISED SYNOVIAL SARCOMA: A RETROSPECTIVE STUDY FROM A TERTIARY CANCER CENTRE IN INDIA
Sushmita Rath
Favorite
(P 438) RANDOMIZED, OPEN-LABEL, PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY VERSUS OBSERVATION IN NON-METASTATIC, HIGH-RISK SOFT TISSUE SARCOMAS (ACO-SARC TRIAL)
Sushmita Rath
Favorite
Raut, Chandrajit

Brigham and Women's Hospital
(P 228) FREQUENCY AND CLARITY OF SURGICAL GOALS FOR TUMOR RESECTION IN ADVANCED SARCOMA
Chandrajit Raut
Favorite
(P 309) RETROPERITONEAL LIPOMAS: MULTICENTER CLINICAL EXPERIENCE WITH AN EXTREMELY RARE DISEASE ENTITY
Chandrajit Raut
Favorite
Ravi, Vinod

The University of Texas MD Anderson Cancer Center
(P 407) PIMICOTINIB IN TENOSYNOVIAL GIANT CELL TUMOR (TGCT): LONG-TERM EFFICACY, SAFETY, AND PATIENT-REPORTED OUTCOMES FROM THE PHASE 3 MANEUVER STUDY
Vinod Ravi
Favorite
(P 422) EFFICACY WITH VIMSELTINIB IN PATIENTS (PTS) WITH TENOSYNOVIAL GIANT CELL TUMOR (TGCT) AND PRIOR COLONY-STIMULATING FACTOR 1 (CSF1) INHIBITOR THERAPY: A PHASE 2 CASE SERIES
Vinod Ravi
Favorite
(P 451) TREATMENT OUTCOMES OF GEMCITABINE AND DOCETAXEL IN PATIENTS WITH CLEAR CELL SARCOMA (CCS) OR GASTROINTESTINAL NEUROECTODERMAL TUMOR (GNET): A CASE SERIES
Vinod Ravi
Favorite
(P 460) OUTCOMES OF LATER-LINES SYSTEMIC THERAPIES IN MALIGNANT PERIPHERAL NERVE SHEATH TUMORS (MPNST)
Vinod Ravi
Favorite
Rayman, Pat

Cleveland Clinic
(P 284) THE IMPACT OF SARCOMA SBRT ON THE IMMUNE SYSTEM: EARLY RESULTS FROM A PROSPECTIVE TRIAL
Pat Rayman
Favorite
Razak, Albiruni

Princess Margaret Cancer Centre
(P 346) SURROGATE ENDPOINTS FOR OVERALL SURVIVAL IN ADVANCED SOFT TISSUE SARCOMA TRIALS: A SYSTEMATIC REVIEW AND META-ANALYSIS
Albiruni Razak
Favorite
(P 395) ERIBULIN IN RECURRENT PRETREATED METASTATIC SOFT TISSUE SARCOMA. A CANADIAN SARCOMA RESEARCH AND CLINICAL COLLABORATION (CANSARCC) REAL WORLD ANALYSIS
Albiruni Razak
Favorite
Razak, Albiruni

Princess Margaret Cancer Center
(P 407) PIMICOTINIB IN TENOSYNOVIAL GIANT CELL TUMOR (TGCT): LONG-TERM EFFICACY, SAFETY, AND PATIENT-REPORTED OUTCOMES FROM THE PHASE 3 MANEUVER STUDY
Albiruni Razak
Favorite
Razmara, Aryana

Surgical Oncology, Department of Surgery, University of California, Davis
(P 244) INTRATUMORAL TIGIT BLOCKADE AUGMENTS ANTI-TUMOR RESPONSES AND BYPASSES HYPERFUNCTIONALITY OF PERIPHERAL TIGIT+ NK CELLS IN MOUSE AND HUMAN MODELS OF BONE AND SOFT TISSUE SARCOMA
Aryana Razmara
Favorite
Rechenauer, Vera Valerie

LMU Munich
(P 443) FIRST-LINE PAZOPANIB IN PATIENTS WITH EPITHELIOID HEMANGIOENDOTHELIOMA: A RETROSPECTIVE SINGLE-CENTER ANALYSIS
Vera Valerie Rechenauer
Favorite
Redding, Joseph

Moffitt Cancer Center
(P 138) A MULTI-INSTITUTIONAL ARCHIVE AND DEEP LEARNING PIPELINE FOR QUANTIFYING CHONDROSARCOMA COMPOSITION
Joseph Redding
Favorite
Redding, Joseph

USF Health Morsani College of Medicine
(P 140) REFINING PRE-SURGICAL ASSESSMENT OF LONG-BONE CHONDROSARCOMA THROUGH THE RADIOLOGIC AGGRESSIVENESS SCORE
Joseph Redding
Favorite
(P 141) A RETROSPECTIVE ANALYSIS OF THE BIRMINGHAM ATYPICAL CARTILAGE TUMOUR IMAGING PROTOCOL (BACTIP) IN MANAGING CENTRAL CARTILAGE TUMORS OF THE LONG BONES
Joseph Redding
Favorite
(P 142) ARE THERE INDEPENDENT PREDICTORS OF DEDIFFERENTIATED CHONDROSARCOMA ON MAGNETIC RESONANCE IMAGING? A MULTIVARIATE ANALYSIS
Joseph Redding
Favorite
(P 145) PATHOLOGIC FRACTURE IN CHONDROSARCOMA OF LONG BONES: A RETROSPECTIVE COHORT STUDY
Joseph Redding
Favorite
(P 160) A COMPARATIVE ANALYSIS OF DEDIFFERENTIATED AND CONVENTIONAL CHONDROSARCOMA OUTCOMES
Joseph Redding
Favorite
Reddy, Chandana

Cleveland Clinic
(P 284) THE IMPACT OF SARCOMA SBRT ON THE IMMUNE SYSTEM: EARLY RESULTS FROM A PROSPECTIVE TRIAL
Chandana Reddy
Favorite
Redmond, Christine

Ratio Therapeutics
(P 430) A PH/2 STUDY OF THE RADIOPHARMACEUTICAL [AC-225]RTX-2358 IN THE TREATMENT OF RELAPSED / REFRACTORY (R/R) SOFT TISSUE SARCOMA (STS) THE ATLAS STUDY - ACTINIUM THERAPY FOR LATE-STAGE AGGRESSIVE SARCOMAS
Christine Redmond
Favorite
Redmond, William

Providence Cancer Institute
(P 58) PLK1 AS A VULNERABLE TARGET OF BAP1-DRIVEN UNDIFFERENTIATED PLEOMORPHIC SARCOMAS
William Redmond
Favorite
Redston, Mark

Brigham and Women's Hospital
(P 235) AGNOSTIC INDICATION OF IMMUNE CHECKPOINT INHIBITORS (ICI): PATTERNS OF RESPONSE OF SARCOMAS
Mark Redston
Favorite
Reed, Damon

Memorial Sloan Kettering
(P 22) SINGLE CELL SEQUENCING ENABLES LINEAGE-INFORMED TARGETING OF OSTEOSARCOMA
Damon Reed
Favorite
(P 187) THERAPEUTIC OUTCOMES IN NF1-ALTERED GIST TREATED WITH MEK INHIBITION: A SINGLE-CENTER EXPERIENCE
Damon Reed
Favorite
(P 256) THE SEAN KARL COHORT: A NATIONAL COLLABORATIVE SINGLE-CELL RNASEQ STUDY OF PAIRED PATIENT EWING SARCOMA SPECIMENS
Damon Reed
Favorite
(P 273) RADIOMIC PREDICTORS OF SPONTANEOUS PNEUMOTHORAX DURING TYROSINE KINASE INHIBITOR THERAPY FOR LUNG METASTASES
Damon Reed
Favorite
(P 467) TREATMENT OUTCOMES IN AGGRESSIVE ANGIOMYXOMA: A SINGLE INSTITUTION EXPERIENCE
Damon Reed
Favorite
Reed, Rebecca

Aveni Foundation
(P 233) DNG64-CAR-V+ REGIMEN SHOWS CLINICAL BENEFIT IN PATIENTS WITH ADVANCED CCNG1 ONCOGENE EXPRESSING SARCOMAS (NCT04091295)
Rebecca Reed
Favorite
Regueiro, Alexandra

Complejo Hospitalario Universitario de Santiago
(P 71) GERMLINE POLYMORPHISMS IN THE VEGF PATHWAY AS PROGNOSTIC BIOMARKERS IN LOCALIZED HIGH-GRADE OSTEOSARCOMA: A STUDY BASED ON DATA FROM THE GEIS-33 PROTOCOL
Alexandra Regueiro
Favorite
Rehman, Shahyan

Yale School of Medicine / Yale New Haven Hospital
(P 40) PRECLINICAL EFFICACY OF A PH-SENSITIVE EXATECAN PEPTIDE-DRUG-CONJUGATE IN RHABDOMYOSARCOMA
Shahyan Rehman
Favorite
Reichardt, Peter

Oncology and Palliative Care / Sarcoma Center Professor of Oncology, Medical School Berlin Chairman of the German Sarcoma Foundation, Helios Klinikum Berlin-Buch
(P 194) UPDATED RESULTS FROM STRATEGIST 1: A PHASE 1/1B STUDY OF IDRX-42 (GSK6042981A) IN PATIENTS (PTS) WITH ADVANCED GASTROINTESTINAL STROMAL TUMORS (GIST)
Peter Reichardt
Favorite
(P 437) CLINICAL DATA CONFIRM GALENIC PRINCIPLE AND DEMONSTRATE THERAPEUTIC POTENTIAL OF THE001 (DPPG2-TSL-DOX) PLUS REGIONAL HYPERTHERMIA IN SOFT TISSUE SARCOMA
Peter Reichardt
Favorite
Reinhorn, Daniel

Memorial Sloan Kettering Cancer Center
(P 186) BRAF V600E-MUTATED GASTROINTESTINAL STROMAL TUMORS: A CASE SERIES AND ANALYSIS OF IMMUNE TUMOR INFILTRATE
Daniel Reinhorn
Favorite
(P 187) THERAPEUTIC OUTCOMES IN NF1-ALTERED GIST TREATED WITH MEK INHIBITION: A SINGLE-CENTER EXPERIENCE
Daniel Reinhorn
Favorite
(P 467) TREATMENT OUTCOMES IN AGGRESSIVE ANGIOMYXOMA: A SINGLE INSTITUTION EXPERIENCE
Daniel Reinhorn
Favorite
Reinisch, Mattea

Department of Gynecology and Obstetrics, University Medical Centre Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
(P 454) TREATMENT PATTERNS AND OUTCOMES IN RADIATION-INDUCED SARCOMA: FIRST RESULTS OF THE TETRIS-PROJECT - A MULTIMODAL RETROSPECTIVE ANALYSIS FROM A TERTIARY CENTER
Mattea Reinisch
Favorite
Reinke, Denise

Sarcoma Patient Advocacy Global Network e.V.
(P 229) DETERMINANTS OF DIAGNOSTIC INTERVAL IN EPITHELIOID HEMANGIOENDOTHELIOMA: A LINEAR AND QUANTILE REGRESSION ANALYSIS OF PATIENT-REPORTED DATA FROM THE SPAGN GLOBAL SARCOMA DIAGNOSIS PATHWAY SURVEY
Denise Reinke
Favorite
(P 450) OUTCOMES IN CLEAR CELL SARCOMA: UPDATED INSIGHTS FROM ELECTRONIC HEALTH RECORDS IN A PATIENT-LED REGISTRY
Denise Reinke
Favorite
Reissfelder, Christoph

Department of Surgery, University Medical Centre Mannheim, Medical Faculty Mannheim, Heidelberg University
(P 165) EVALUATING LARGE LANGUAGE MODELS AS DECISION SUPPORT TOOLS IN MULTIDISCIPLINARY TUMOR BOARDS FOR GASTROINTESTINAL STROMAL TUMORS
Christoph Reissfelder
Favorite
(P 169) BENCHMARKING LARGE LANGUAGE MODELS VS MULTIDISCIPLINARY TUMOR BOARDS OF 21 SARCOMA CENTERS
Christoph Reissfelder
Favorite
(P 303) MULTIVISCERAL RESECTIONS AND URINARY TRACT RECONSTRUCTION TECHNIQUES IN THE SURGERY OF RETROPERITONEAL SARCOMAS: A CASE SERIES.
Christoph Reissfelder
Favorite
(P 312) APOSST: A PROSPECTIVE TRIAL TO EVALUATE ACUPUNCTURE AFTER SURGERY OF EXTREMITY SOFT TISSUE TUMORS
Christoph Reissfelder
Favorite
(P 367) ADHERENCE TO GERMAN SARCOMA GUIDELINE FOR MRI SEQUENCING IN SOFT TISSUE SARCOMA: EVALUATION OF IMAGING PRACTICES AND COMPLIANCE
Christoph Reissfelder
Favorite
(P 441) COLOSARC-Q: A PROSPECTIVE MULTICENTER STUDY FOR EVALUATING SURGICAL STRATEGIES FOR COLORECTAL RESECTIONS AND POSTOPERATIVE QUALITY OF LIFE IN RETROPERITONEAL SARCOMA PATIENTS
Christoph Reissfelder
Favorite
(P 454) TREATMENT PATTERNS AND OUTCOMES IN RADIATION-INDUCED SARCOMA: FIRST RESULTS OF THE TETRIS-PROJECT - A MULTIMODAL RETROSPECTIVE ANALYSIS FROM A TERTIARY CENTER
Christoph Reissfelder
Favorite
Rejas Mateo, Alicia

Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan
(P 277) THE ROLE OF RADIOTHERAPY IN THE MULTIDISCIPLINARY MANAGEMENT OF RADIATION-ASSOCIATED ANGIOSARCOMA OF THE BREAST: A REFERRAL CENTER EXPERIENCE
Alicia Rejas Mateo
Favorite
Rekhi, Bharat

Tata Memorial Hospital
(P 286) INTERSTITIAL BRACHYTHERAPY FOR ORGAN AND FUNCTION PRESERVATION IN SOFT TISSUE SARCOMAS: LONG TERM OUTCOMES
Bharat Rekhi
Favorite
(P 338) POORLY DIFFERENTIATED SYNOVIAL SARCOMA: A HISTOLOGIC CHALLENGE OF AN AGGRESSIVE VARIANT
Bharat Rekhi
Favorite
(P 379) IMPACT OF EWSR1 GENE REARRANGEMENT TESTING ON DIAGNOSIS OF A WIDE RANGE OF SOLID TUMOURS
Bharat Rekhi
Favorite
(P 387) TREATMENT PATTERNS AND PROGNOSTIC FACTORS IN LOCALISED SYNOVIAL SARCOMA: A RETROSPECTIVE STUDY FROM A TERTIARY CANCER CENTRE IN INDIA
Bharat Rekhi
Favorite
(P 438) RANDOMIZED, OPEN-LABEL, PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY VERSUS OBSERVATION IN NON-METASTATIC, HIGH-RISK SOFT TISSUE SARCOMAS (ACO-SARC TRIAL)
Bharat Rekhi
Favorite
(P 463) EXTRANODAL FOLLICULAR DENDRITIC CELL SARCOMAS AND THEIR OLIGORECURRENCES: TRIUMPHS, TRIALS AND LESSONS LEARNT AT A SINGLE TERTIARY CANCER REFERRAL CENTRE, INDIA.
Bharat Rekhi
Favorite
Rekulapelli, Akhil

Vanderbilt University School of Medicine
(P 97) RISK FACTORS ASSOCIATED WITH AMPUTATION VERSUS CONTINUED LIMB SALVAGE IN LOWER EXTREMITY ENDOPROSTHETIC RECONSTRUCTION
Akhil Rekulapelli
Favorite
Remiszewski, Piotr

Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland
(P 134) INTEGRATIVE MICRORNA PROFILING IN CHONDROSARCOMA: TOWARD BIOMARKER DISCOVERY AND PROGNOSTIC SIGNATURE DEVELOPMENT
Piotr Remiszewski
Favorite
(P 146) LOCALISED CHONDROSARCOMA PERIOPERATIVE TREATMENT: REAL-WORLD OUTCOMES AND CHALLENGES ACROSS HISTOLOGIC SUBTYPES
Piotr Remiszewski
Favorite
(P 149) SURGICAL TEXTBOOK OUTCOMES IN PATIENTS DIAGNOSED WITH CHONDROSARCOMA
Piotr Remiszewski
Favorite
(P 152) EFFICACY OF PALLIATIVE CHEMOTHERAPY AND LOCAL TREATMENTS IN ADVANCED CHONDROSARCOMA: A SUBTYPE-SPECIFIC RETROSPECTIVE ANALYSIS
Piotr Remiszewski
Favorite
(P 164) LONG TERM OUTCOMES IN PATIENTS DIAGNOSED WITH SECONDARY CHONDROSARCOMA
Piotr Remiszewski
Favorite
Ren, Tingting

Peking University People's Hospital
(P 74) TERTIARY LYMPHOID STRUCTURES PREDICT PROGNOSIS AND IMMUNE LANDSCAPE IN OSTEOSARCOMA: A MACHINE LEARNING-BASED TRANSCRIPTOMIC STUDY
Tingting Ren
Favorite
(P 75) CD248 AS A PROGNOSTIC MARKER IN OSTEOSARCOMA
Tingting Ren
Favorite
Rerko, Matthew

Cleveland Clinic
(P 316) AREA DEPRIVATION INDEX (ADI) AND OUTCOMES IN LOCALIZED SOFT TISSUE SARCOMA: DO SOCIAL DETERMINANTS INFLUENCE SURVIVAL?
Matthew Rerko
Favorite
Restrepo, Juliana

Fundación Colombiana de Cancerología Clínica Vida, Clínica Astorga
(P 219) RETROPERITONEAL SARCOMA: HEALTH SYSTEM BARRIERS AND THE RATIONALE FOR A SPECIALIZED SARCOMA UNIT
Juliana Restrepo
Favorite
(P 301) RETROPERITONEAL SARCOMA: SINGLE CENTER EXPERIENCE IN LATIN AMERICA. DO WE HAVE DIFFERENT SARCOMAS WHEN COMPARED TO THE REST OF THE WORLD?
Juliana Restrepo
Favorite
Restrepo, Sofia

University of South Florida, Morsani College of Medicine
(P 163) CHONDROSARCOMA IN THE AYA POPULATION
Sofia Restrepo
Favorite
Reu, Frederic

Deciphera Pharmaceuticals, LLC
(P 424) AN OPEN-LABEL PHASE 1/2 STUDY OF DCC-3009 MONOTHERAPY IN PATIENTS (PTS) WITH ADVANCED GASTROINTESTINAL STROMAL TUMOR (GIST)
Frederic Reu
Favorite
Rey, Christophe

Institut Bergonié
(P 59) TARGETING ADORA2B TO HALT METASTASIS IN UNDIFFERENTIATED PLEOMORPHIC SARCOMA: FROM MULTI-OMICS TO THERAPEUTIC INHIBITION
Christophe Rey
Favorite
Rhoades, Julie

Vanderbilt University Medical Center
(P 51) OVEREXPRESSION OF GLI2 IN DEDIFFERENTIATED LIPOSARCOMA TUMORS INDUCES MICROENVIRONMENT REMODELING
Julie Rhoades
Favorite
Rhodes, Whitney

Genesis Research Group
(P 464) EFFICACY OUTCOMES AMONG PATIENTS WITH ADVANCED EPITHELIOID SARCOMAS OF PROXIMAL-TYPE AND DISTAL-TYPE TREATED WITH TAZ: POST HOC ANALYSIS OF STUDY EZH-202
Whitney Rhodes
Favorite
Ribas, Roberto

University of Florida
(P 129) HIJACKED FUEL: GLYCOGEN-DRIVEN METABOLIC SHIFTS IN IDH1-MUTANT CHONDROSARCOMA
Roberto Ribas
Favorite
Ribeiro, Mauricio

Moffitt Cancer Center
(P 394) DUAL OR TRIMODALITY THERAPY VERSUS SURGERY ALONE IN RADIATION-ASSOCIATED ANGIOSARCOMA OF THE BREAST
Mauricio Ribeiro
Favorite
(P 453) OUTCOMES OF PLEOMORPHIC LIPOSARCOMA PATIENTS FOLLOWING MULTI-DISCIPLINARY MANAGEMENT WITHIN A TERTIARY CANCER CENTER
Mauricio Ribeiro
Favorite
Ricchinin, Francesca

Fondazione IRCCS Istituto Nazionale dei Tumori di Milano
(P 447) PAIN ASSESSMENT CRITERIA (PAC) ANTICIPATE RECIST PROGRESSION AND CORRELATE WITH BLOOD LEVELS OF GROWTH DIFFERENTIATION FACTOR 15 (GDF15) IN EPITHELIOID HEMANGIOENDOTHELIOMA (EHE)
Francesca Ricchinin
Favorite
Richardson, Spencer

Indiana University
(P 82) DISPARITIES IN OSTEOSARCOMA BY SOCIOECONOMIC STATUS
Spencer Richardson
Favorite
(P 84) A MULTICENTER COMPARISON OF REVERSE TOTAL SHOULDER ARTHROPLASTY VERSUS HEMIARTHROPLASTY FOR ENDOPROSTHETIC RECONSTRUCTION FOLLOWING ONCOLOGIC RESECTION OF THE PROXIMAL HUMERUS
Spencer Richardson
Favorite
(P 269) INCIDENCE OF MALIGNANCY IN BIOPSIED PEDIATRIC SOFT TISSUE MASSES
Spencer Richardson
Favorite
(P 272) THE HAZARDS OF BIOPSY IN PEDIATRIC SOFT TISSUE SARCOMAS
Spencer Richardson
Favorite
Ridgway, Paul

St Vincent's University Hospital
(P 211) HEALTH-RELATED QUALITY OF LIFE IN IRISH SARCOMA PATIENTS
Paul Ridgway
Favorite
(P 213) FINANCIAL TOXICITY IN IRISH SARCOMA CARE: A SINGLE-CENTRE ANALYSIS
Paul Ridgway
Favorite
Riedel, Richard

Duke Cancer Institute
(P 413) EFFICACY OF NIROGACESTAT IN PATIENTS WITH DESMOID TUMORS AND PRESENCE OR ABSENCE OF POOR PROGNOSTIC FACTORS: POST HOC ANALYSES OF THE PHASE 3 DEFI TRIAL
Richard Riedel
Favorite
Riesterer, Oliver

Center of Radiation Oncology, Cantonal Hospital Aarau
(P 436) SAKK 57/24 FEASIBILITY OF TOTAL NEOADJUVANT TREATMENT WITH HYPERTHERMIA IN PATIENTS WITH HIGH-RISK EXTREMITY AND TRUNK SOFT TISSUE SARCOMA. A MULTICENTER, SINGLE ARM, OPEN LABEL, PHASE II TRIAL
Oliver Riesterer
Favorite
Rieth, John

University of Iowa
(P 343) PROGRESSION FREE SURVIVAL OF IMMUNE CHECKPOINT INHIBITORS IN THE FIRST-LINE TREATMENT OF METASTATIC SARCOMA: A SINGLE CENTER RETROSPECTIVE ANALYSIS.
John Rieth
Favorite
(P 370) CLINICAL OUTCOMES OF CUTANEOUS UNDIFFERENTIATED PLEOMORPHIC SARCOMA AND SUBCUTANEOUS MYXOFIBROSARCOMA: A RETROSPECTIVE REVIEW
John Rieth
Favorite
(P 371) CLINICAL PROFILE AND TREATMENT PATTERNS OF ANGIOSARCOMA IN THE REAL- WORLD SETTING: A SINGLE CENTER EXPERIENCE FROM 1991-2024.
John Rieth
Favorite
(P 439) AN OPEN LABEL MULTICENTER PHASE 2 STUDY WITH SAFETY LEAD IN OF INTRATUMORAL VUSOLIMOGENE ODERPAREPVEC IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH ANGIOSARCOMA
John Rieth
Favorite
Riggs, Keegan

Indiana University School of Medicine
(P 269) INCIDENCE OF MALIGNANCY IN BIOPSIED PEDIATRIC SOFT TISSUE MASSES
Keegan Riggs
Favorite
(P 272) THE HAZARDS OF BIOPSY IN PEDIATRIC SOFT TISSUE SARCOMAS
Keegan Riggs
Favorite
Righi, Alberto

IRCCS Istituto Ortopedico Rizzoli
(P 139) IMMUNOGENOMIC PROFILING OF CHONDROSARCOMA REVEALS DISTINCT IMMUNE PHENOTYPES AND PROGNOSTIC MUTATIONS
Alberto Righi
Favorite
(P 151) SHOULD WE USE ADJUVANT CHEMOTHERAPY IN PATIENTS WITH LOCALIZED DEDIFFERENTIATED CHONDROSARCOMA (DDCS) OF THE PELVIS? AN ANALYSIS BY THE PELVIC DDCS STUDY GROUP
Alberto Righi
Favorite
Riley, Dylan

Rush University Medical Center
(P 104) 3D PRINTED CUTTING GUIDES FOR LONG BONE SARCOMA RESECTION AND INTERCALARY ALLOGRAFT RECONSTRUCTION: A CASE SERIES
Dylan Riley
Favorite
(P 113) ASSESSING TREATMENT OUTCOMES OF CHONDROMYXOID FIBROMA: A CASE SERIES
Dylan Riley
Favorite
(P 206) IMPACT OF PROXIMITY TO HEALTH CENTER ON ADHERENCE TO NATIONAL COMPREHENSIVE CANCER NETWORK GUIDELINES IN PATIENTS WITH SOFT TISSUE SARCOMAS
Dylan Riley
Favorite
Risi Ambrogioni, Laura

Università Campus Bio-Medico di Roma
(P 412) UNCOVERING HER2 OVEREXPRESSION IN SOFT TISSUE SARCOMAS (STS): INSIGHTS FROM THE CANCER GENOME ATLAS (TCGA)
Laura Risi Ambrogioni
Favorite
Ritterhouse, Lauren

Department of Pathology, Center for Integrated Diagnostics, Massachusetts General Hospital and Harvard Medical School
(P 45) MONITORING EWSR1 FUSIONS IN SARCOMA PATIENTS USING PERSONALIZED LIQUID BIOPSY ASSAYS
Lauren Ritterhouse
Favorite
Rivera Carrasquillo, Paula

University of Puerto Rico
(P 40) PRECLINICAL EFFICACY OF A PH-SENSITIVE EXATECAN PEPTIDE-DRUG-CONJUGATE IN RHABDOMYOSARCOMA
Paula Rivera Carrasquillo
Favorite
Rivera, Dyani

Children's Hospital of Philadelphia
(P 262) EVALUATING FRONT-LINE THERAPY ACCORDANCE WITH CURRENT SYNOVIAL SARCOMA GUIDELINES
Dyani Rivera
Favorite
(P 263) DESCRIBING THE CHARACTERISTICS AND TREATMENT OF SYNOVIAL SARCOMA IN THE RECURRENT SETTING
Dyani Rivera
Favorite
Rivera, Miguel

Massachusetts General Hospital
(P 24) THE SIRTUIN SIRT5 SUPPORTS EWING SARCOMA SURVIVAL VIA REGULATION OF EWS-FLI1 STABILITY AND ACTIVITY
Miguel Rivera
Favorite
Robba, Tiziana

Radiology, Ospedale CTO, AOU Città della Salute e della Scienza di Torino
(P 231) INCREASED LIFETIME RISK (LTR) OF SOFT TISSUE SARCOMAS (STS) IN PATIENTS WITH LOW-RISK GASTROINTESTINAL STROMAL TUMORS (GIST): A RETROSPECTIVE ANALYSIS FROM THE ITALIAN SARCOMA GROUP (ISG)
Tiziana Robba
Favorite
Robbins, Elizabeth

Cure 4 The Kids Foundation
(P 261) SUSTAINED RESPONSE WITH RIVOCERANIB AND DENOSUMAB IN RELASPED OSTEOSARCOMA
Elizabeth Robbins
Favorite
Robbins, Julia

TalusBio
(P 260) MECHANISM AND EFFICACY OF ANTHRACYCLINE MEDIATED EPIGENETIC DISRUPTION IN BONE SARCOMAS.
Julia Robbins
Favorite
Roberts, Evan

3. Sylvester Comprehensive Cancer Center
(P 31) TARGETING CANCER STEM CELLS BY TYROSINE PEPTIDE ANALOGUE IN REFRACTORY SARCOMA
Evan Roberts
Favorite
Roberts, Jesse

Fred Hutchinson Cancer Center
(P 287) A PHASE 1 STUDY OF NEOADJUVANT CABOZANTINIB IN COMBINATION WITH RADIATION THERAPY FOR SARCOMAS OF THE EXTREMITIES
Jesse Roberts
Favorite
Roberts, Ryan

Nationwide Children's Hospital
(P 08) BUILDING A MEDICAL DONATION NETWORK TO ENHANCE DEVELOPMENT OF PEDIATRIC TUMOR MODELS
Ryan Roberts
Favorite
(P 13) TRANSCRIPTIONAL DIVERSITY AND NICHE REMODELING AT THE METASTATIC BOTTLENECK IN OSTEOSARCOMA
Ryan Roberts
Favorite
Robinson, Denise

The EHE Foundation
(P 444) HEALTH-RELATED QUALITY OF LIFE (HRQOL) CHALLENGES IN PATIENTS WITH EPITHELIOID HEMANGIOENDOTHELIOMA (EHE): ANALYSIS OF AN ULTRA-RARE SARCOMA GROUP
Denise Robinson
Favorite
(P 446) GDF-15 AS A PROGNOSTIC FACTOR IN PATIENTS WITH EPITHELIOID HEMANGIOENDOTHELIOMA
Denise Robinson
Favorite
(P 447) PAIN ASSESSMENT CRITERIA (PAC) ANTICIPATE RECIST PROGRESSION AND CORRELATE WITH BLOOD LEVELS OF GROWTH DIFFERENTIATION FACTOR 15 (GDF15) IN EPITHELIOID HEMANGIOENDOTHELIOMA (EHE)
Denise Robinson
Favorite
(P 448) OVERCOMING CHALLENGES IN ULTRA-RARE SARCOMAS: A CENTRALIZED BIOBANK FOR EPITHELIOID HEMANGIOENDOTHELIOMA AS A RESOURCE TO ACCELERATE DISCOVERY
Denise Robinson
Favorite
(P 449) UNDERSTANDING GAPS IN KNOWLEDGE AND PATIENT-REPORTED PAIN IN EPITHELIOID HEMANGIOENDOTHELIOMA: RESULTS FROM A GLOBAL PATIENT REGISTRY
Denise Robinson
Favorite
Robinson, James

Children's Hospital of Philadelphia
(P 262) EVALUATING FRONT-LINE THERAPY ACCORDANCE WITH CURRENT SYNOVIAL SARCOMA GUIDELINES
James Robinson
Favorite
(P 263) DESCRIBING THE CHARACTERISTICS AND TREATMENT OF SYNOVIAL SARCOMA IN THE RECURRENT SETTING
James Robinson
Favorite
Robinson, Steven

Mayo Clinic
(P 223) OUTCOMES OF GERIATRIC PATIENTS WITH DE NOVO SARCOMA AND LUNG METASTASES: ROLE OF TUMOR CHARACTERISTICS AND TREATMENT STRATEGY
Steven Robinson
Favorite
(P 246) CTLA4 PATHWAY ACTIVATION IN RADIATION-INDUCED ANGIOSARCOMA: A TRANSCRIPTOMIC RATIONALE FOR IMMUNE CHECKPOINT BLOCKADE
Steven Robinson
Favorite
(P 300) FEATURES AND OUTCOMES OF PATIENTS WITH GASTROINTESTINAL LEIYOMYOSARCOMA
Steven Robinson
Favorite
Rochaix, Philippe

OCR
(P 28) ADVANCING PRECISION ONCOLOGY IN SOFT TISSUE SARCOMAS: THE ROLE OF ITRAC IN METASTATIC RISK STRATIFICATION AND TREATMENT PERSONALIZATION
Philippe Rochaix
Favorite
Rodenbarger, Lauren

LabCorp Central Laboratory Services
(P 24) THE SIRTUIN SIRT5 SUPPORTS EWING SARCOMA SURVIVAL VIA REGULATION OF EWS-FLI1 STABILITY AND ACTIVITY
Lauren Rodenbarger
Favorite
Rodon, Jordi

The University of Texas MD Anderson Cancer Center
(P 184) MTAP IN GASTROINTESTINAL STROMAL TUMOR (GIST): RATE OF MTAP LOSS AND CONCORDANCE BETWEEN GENOMIC SEQUENCING AND IMMUNOHISTOCHEMISTRY
Jordi Rodon
Favorite
(P 415) A PHASE 1/2 TRIAL OF FOG-001, A FIRST-IN-CLASS DIRECT β-CATENIN:TCF4 INHIBITOR: SAFETY AND PRELIMINARY ANTITUMOR ACTIVITY IN PATIENTS WITH DESMOID TUMORS (DT)
Jordi Rodon
Favorite
(P 434) A FIRST-IN-HUMAN PHASE 1, MULTICENTER, OPEN-LABEL STUDY OF M3554, A NOVEL ANTI-GD2 ANTIBODY-DRUG CONJUGATE, IN PATIENTS WITH ADVANCED SOLID TUMORS
Jordi Rodon
Favorite
Rodriguez Izquierdo, Frida

Universidad Autónoma Metropolitana
(P 39) BUB1 AN OVEREXPRESSED KINASE IN SARCOMA: FINDING NEW TARGET THERAPY FOR OSTEOSARCOMA, LIPOSARCOMA, SYNOVIAL SARCOMA AND LEIOMYOSARCOMA
Frida Rodriguez Izquierdo
Favorite
Rodriguez Morales, Miguel

Instituto Nacional de Pediatria
(P 39) BUB1 AN OVEREXPRESSED KINASE IN SARCOMA: FINDING NEW TARGET THERAPY FOR OSTEOSARCOMA, LIPOSARCOMA, SYNOVIAL SARCOMA AND LEIOMYOSARCOMA
Miguel Rodriguez Morales
Favorite
Rodriguez, Maressa

University of California Davis School of Medicine
(P 77) BARRIERS TO GUIDELINE CONCORDANT CARE IN AYA PATIENTS WITH BONE SARCOMAS
Maressa Rodriguez
Favorite
Rodriguez-Wallberg, Kenny

Karolinska Hospital and Institute
(P 270) FEASIBILITY OF FERTILITY PRESERVATION IN CHILDREN, ADOLESCENTS AND YOUNG ADULTS WITH SARCOMAS - A PROSPECTIVE COHORT STUDY WITH LONG-TERM FOLLOW-UP
Kenny Rodriguez-Wallberg
Favorite
Rogala, Pawel

National Research Institute of Oncology Warsaw Poland
(P 123) OFF-LABEL DENOSUMAB IN LOCALLY AGGRESSIVE BENIGN BONE TUMORS OTHER THAN GIANT CELL TUMOR OF BONE.
Pawel Rogala
Favorite
Rogala, Pawel

Maria Sklodowska-Curie National Research Institute of Oncology
(P 470) OFF-LABEL TREATMENT AND ULTRARARE SARCOMAS - SINGLE INSTITUTION REPORT
Pawel Rogala
Favorite
Rogers, Alan

The Ohio State University
(P 153) DOES THE QUANTITY OF DEDIFFERENTIATION MATTER IN THE CLINICAL OUTCOMES OF DEDIFFERENTIATED CHONDROSARCOMA? A 10-YEAR SINGLE TERTIARY INSTITUTIONAL EXPERIENCE OF A SERIES.
Alan Rogers
Favorite
Rojas, Santiago

Fundación Colombiana de Cancerología Clínica Vida, Hospital San Vicente Fundación
(P 219) RETROPERITONEAL SARCOMA: HEALTH SYSTEM BARRIERS AND THE RATIONALE FOR A SPECIALIZED SARCOMA UNIT
Santiago Rojas
Favorite
(P 301) RETROPERITONEAL SARCOMA: SINGLE CENTER EXPERIENCE IN LATIN AMERICA. DO WE HAVE DIFFERENT SARCOMAS WHEN COMPARED TO THE REST OF THE WORLD?
Santiago Rojas
Favorite
Rojo, Jonathan

Parabilis Medicines
(P 415) A PHASE 1/2 TRIAL OF FOG-001, A FIRST-IN-CLASS DIRECT β-CATENIN:TCF4 INHIBITOR: SAFETY AND PRELIMINARY ANTITUMOR ACTIVITY IN PATIENTS WITH DESMOID TUMORS (DT)
Jonathan Rojo
Favorite
Roland, Christina

The University of Texas MD Anderson Cancer Center
(P 172) COMPARISON OF CELL SEGMENTATION METHODS IN SOFT TISSUE SARCOMA (STS) SPATIAL PROTEOMIC DATASETS
Christina Roland
Favorite
(P 242) IMMUNE PROFILING OF UNDIFFERENTIATED PLEOMORPHIC SARCOMAS REVEALS DISTINCT PROGNOSTIC SUBGROUPS
Christina Roland
Favorite
(P 351) THE ROLE OF SOCIOECONOMIC DISPARITIES ON SURVIVAL OUTCOMES IN MALIGNANT PERIPHERAL NERVE SHEATH TUMORS
Christina Roland
Favorite
Romandini, Davide

Università Campus Bio-Medico di Roma
(P 412) UNCOVERING HER2 OVEREXPRESSION IN SOFT TISSUE SARCOMAS (STS): INSIGHTS FROM THE CANCER GENOME ATLAS (TCGA)
Davide Romandini
Favorite
Romano Cardozo, Alejandra

Hospital Santa Creu i Sant Pau
(P 218) THE IMPACT OF BROADENED GENETIC COUNSELLING REFERRAL CRITERIA IN SARCOMA PATIENTS: A REFERENCE CENTRE'S EXPERIENCE
Alejandra Romano Cardozo
Favorite
Ronan, Karine

St Vincent's University Hospital
(P 211) HEALTH-RELATED QUALITY OF LIFE IN IRISH SARCOMA PATIENTS
Karine Ronan
Favorite
(P 213) FINANCIAL TOXICITY IN IRISH SARCOMA CARE: A SINGLE-CENTRE ANALYSIS
Karine Ronan
Favorite
Roohani, Siyer

Department of Radiation Oncology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin
(P 169) BENCHMARKING LARGE LANGUAGE MODELS VS MULTIDISCIPLINARY TUMOR BOARDS OF 21 SARCOMA CENTERS
Siyer Roohani
Favorite
Rosales, Wesley

Providence Cancer Institute
(P 58) PLK1 AS A VULNERABLE TARGET OF BAP1-DRIVEN UNDIFFERENTIATED PLEOMORPHIC SARCOMAS
Wesley Rosales
Favorite
Rose, Brandon

University of Texas Southwestern Medical Center
(P 217) PATIENT QUESTIONNAIRE EXPLORING THE PRE-SARCOMA DIAGNOSIS CHARACTERISTICS OF SARCOMA PATIENTS
Brandon Rose
Favorite
(P 224) PAN-SARCOMA DATABASE (PSDB): AN UPDATE ON MIAMI'S COLLABORATIVE MULTI-USER DATA PIPELINE OF SARCOMA DATA USING REDCAP AND R CODING
Brandon Rose
Favorite
(P 320) CLINICAL CHARACTERISTICS AND RECURRENCE PATTERNS IN HISPANIC VS. NON-HISPANIC PATIENTS WITH LEIOMYOSARCOMA: FINDINGS FROM A RETROSPECTIVE SINGLE-CENTER COHORT STUDY
Brandon Rose
Favorite
(P 327) INITIAL TREATMENT MODALITY AND RECURRENCE IN NON-METASTATIC LEIOMYOSARCOMA: A RETROSPECTIVE COHORT STUDY
Brandon Rose
Favorite
(P 333) METABOLIC SYNDROME CORRELATION WITH LIPOSARCOMA INCIDENCE AND OUTCOMES: A RETROSPECTIVE ANALYSIS.
Brandon Rose
Favorite
(P 362) SHOULD PAZOPANIB BE USED AS A MAINTENANCE THERAPY TO IMPROVE RECURRENCE-FREE SURVIVAL AND OVERALL SURVIVAL IN PATIENTS WHO RECEIVED MAI IN SOFT TISSUE SARCOMA?
Brandon Rose
Favorite
(P 369) CLINICAL CHARACTERISTICS & TREATMENT OUTCOME PATTERNS OF SOLITARY FIBROUS TUMORS: A SINGLE-INSTITUTION RETROSPECTIVE ANALYSIS
Brandon Rose
Favorite
(P 397) EXPLORING REAL WORLD DATA OF RECURRENCE IN NON-METASTATIC MYXOFIBROSAROMA: AN UPDATED RETROSPECTIVE COHORT STUDY
Brandon Rose
Favorite
Rosenbaum, Evan

Memorial Sloan Kettering Cancer Center
(P 187) THERAPEUTIC OUTCOMES IN NF1-ALTERED GIST TREATED WITH MEK INHIBITION: A SINGLE-CENTER EXPERIENCE
Evan Rosenbaum
Favorite
(P 409) RETROSPECTIVE ANALYSIS OF PROGNOSTIC FACTORS INCLUDING HLA GENOTYPE IN MYXOID LIPOSARCOMA
Evan Rosenbaum
Favorite
(P 421) CHARACTERIZING THE IMMUNE RESPONSE TO INTRATUMORAL TIGILANOL TIGLATE (TT) IN PATIENTS WITH ADVANCED AND/OR METASTATIC SOFT TISSUE SARCOMA (STS) IN A PHASE IIA TRIAL (NCT05755113)
Evan Rosenbaum
Favorite
(P 467) TREATMENT OUTCOMES IN AGGRESSIVE ANGIOMYXOMA: A SINGLE INSTITUTION EXPERIENCE
Evan Rosenbaum
Favorite
Rosenberg, Andrew

University of Miami
(P 147) CONVENTIONAL AND DEDIFFERENTIATED CHONDROSARCOMA; IS ENCHONDROMA THE PRECURSOR LESION?
Andrew Rosenberg
Favorite
(P 154) BCOR-MUTATED CONVENTIONAL AND DEDIFFERENTIATED CHONDROSARCOMA: A CLINICOPATHOLOGIC STUDY
Andrew Rosenberg
Favorite
(P 225) GLOBAL REGISTRY OF SOLITARY FIBROUS TUMORS (SFT): INTEGRATING CLINICAL, MOLECULAR, AND ENVIRONMENTAL DATA- THE HOROWITZ SFT INITIATIVE (HSFTI)
Andrew Rosenberg
Favorite
(P 289) SIX YEAR FOLLOW-UP ON CIVASHEET® USE FOR SOFT TISSUE SARCOMA: A SINGLE INSTITUTION EXPERIENCE
Andrew Rosenberg
Favorite
(P 320) CLINICAL CHARACTERISTICS AND RECURRENCE PATTERNS IN HISPANIC VS. NON-HISPANIC PATIENTS WITH LEIOMYOSARCOMA: FINDINGS FROM A RETROSPECTIVE SINGLE-CENTER COHORT STUDY
Andrew Rosenberg
Favorite
(P 327) INITIAL TREATMENT MODALITY AND RECURRENCE IN NON-METASTATIC LEIOMYOSARCOMA: A RETROSPECTIVE COHORT STUDY
Andrew Rosenberg
Favorite
(P 362) SHOULD PAZOPANIB BE USED AS A MAINTENANCE THERAPY TO IMPROVE RECURRENCE-FREE SURVIVAL AND OVERALL SURVIVAL IN PATIENTS WHO RECEIVED MAI IN SOFT TISSUE SARCOMA?
Andrew Rosenberg
Favorite
(P 369) CLINICAL CHARACTERISTICS & TREATMENT OUTCOME PATTERNS OF SOLITARY FIBROUS TUMORS: A SINGLE-INSTITUTION RETROSPECTIVE ANALYSIS
Andrew Rosenberg
Favorite
(P 393) DISTINCT SECONDARY MUTATIONAL LANDSCAPES ARE ASSOCIATED WITH NAB2–STAT6 FUSION BREAKPOINTS IN SOLITARY FIBROUS TUMORS
Andrew Rosenberg
Favorite
Rosenthal, Howard

University of Kansas Medical Center
(P 366) WOUND COMPLICATIONS AFTER ULTRA-HYPOFRACTIONATED NEOADJUVANT RADIATION FOR SOFT TISSUE SARCOMA: WHAT IS OPTIMAL SURGICAL TIMING?
Howard Rosenthal
Favorite
Rose, Peter

Mayo Clinic
(P 223) OUTCOMES OF GERIATRIC PATIENTS WITH DE NOVO SARCOMA AND LUNG METASTASES: ROLE OF TUMOR CHARACTERISTICS AND TREATMENT STRATEGY
Peter Rose
Favorite
Rose, Raven

Memorial Sloan Kettering Cancer Center
(P 08) BUILDING A MEDICAL DONATION NETWORK TO ENHANCE DEVELOPMENT OF PEDIATRIC TUMOR MODELS
Raven Rose
Favorite
Rosinski, Jenna

Seattle Children's Research Institute
(P 260) MECHANISM AND EFFICACY OF ANTHRACYCLINE MEDIATED EPIGENETIC DISRUPTION IN BONE SARCOMAS.
Jenna Rosinski
Favorite
Rossing, Maria

Center for Genomic Medicine, Copenhagen University Hospital, Rigshospitalet
(P 05) CONCORDANCE OF GENOMIC ALTERATIONS WITH CIRCULATING TUMOR DNA: INITIAL FINDINGS FROM A PILOT STUDY
Maria Rossing
Favorite
Ross, Jeffrey

SUNY Upstate Medical University
(P 393) DISTINCT SECONDARY MUTATIONAL LANDSCAPES ARE ASSOCIATED WITH NAB2–STAT6 FUSION BREAKPOINTS IN SOLITARY FIBROUS TUMORS
Jeffrey Ross
Favorite
Roth, Clark

University of Pittsburgh Medical Center
(P 63) EVALUATING SURGICAL MARGINS IN SARCOMA RESECTION WITH INDOCYANINE GREEN FLUORESCENCE IMAGING
Clark Roth
Favorite
Roth, Mike

MD Anderson
(P 77) BARRIERS TO GUIDELINE CONCORDANT CARE IN AYA PATIENTS WITH BONE SARCOMAS
Mike Roth
Favorite
Rothschild, Sara

Life Raft Group
(P 190) TEMPORAL DECLINE IN PROGRESSION-FREE SURVIVAL, TIME ON MEDICATION, AND OVERALL SURVIVAL IN ADVANCED GASTROINTESTINAL STROMAL TUMOR
Sara Rothschild
Favorite
(P 226) REAL-WORLD MANAGEMENT OF SYMPTOMATIC VS ASYMPTOMATIC TGCT FROM AN OBSERVATIONAL REGISTRY
Sara Rothschild
Favorite
Rotondo, Ronny

University of Kansas Medical Center
(P 366) WOUND COMPLICATIONS AFTER ULTRA-HYPOFRACTIONATED NEOADJUVANT RADIATION FOR SOFT TISSUE SARCOMA: WHAT IS OPTIMAL SURGICAL TIMING?
Ronny Rotondo
Favorite
Rougraff, Bruce

IndyOrtho
(P 272) THE HAZARDS OF BIOPSY IN PEDIATRIC SOFT TISSUE SARCOMAS
Bruce Rougraff
Favorite
Rousi, Emma

ORION PHARMA
(P 445) TEADES PH1/2 STUDY WITH ODM-212: PRELIMINARY RESULTS IN EHE PATIENTS
Emma Rousi
Favorite
Roussel, Natacha

Toulouse Cancer Research Center - INSERM
(P 20) IDENTIFICATION OF A PROGNOSTIC GENE SIGNATURE FOR OSTEOSARCOMA RELAPSE BASED ON RESIDUAL TUMOR DISEASE AND ITS MICROENVIRONMENT
Natacha Roussel
Favorite
Ruano, Dina

Leiden University Medical Center
(P 127) AN INTEGRATED CLINICAL GENOMIC AND TRANSCRIPTOMIC SUBGROUPING OF CENTRAL CHONDROSARCOMA
Dina Ruano
Favorite
Rubin, Brian

Cleveland Clinic
(P 284) THE IMPACT OF SARCOMA SBRT ON THE IMMUNE SYSTEM: EARLY RESULTS FROM A PROSPECTIVE TRIAL
Brian Rubin
Favorite
Ruffing, Cooper

Duke University
(P 130) INVESTIGATING LCP1-MEDIATED ONCOGENIC SIGNALING IN CHONDROSARCOMA METASTASIS
Cooper Ruffing
Favorite
Rumana, Rachel

Universtity of Miami Miller School of Medicine
(P 89) PATELLAR HEIGHT AND ITS INFLUENCE ON FUNCTIONAL OUTCOMES FOR MEGAPROSTHESES AROUND THE KNEE PERFORMED FOR ONCOLOGICAL INDICATIONS
Rachel Rumana
Favorite
Ruppert, Nathaniel

Case Western Reserve University School of Medicine
(P 457) A RETROSPECTIVE REVIEW OF LOW-GRADE FIBROMYXOID SARCOMA: SURGICAL MANAGEMENT, RADIATION THERAPY, AND OUTCOMES
Nathaniel Ruppert
Favorite
Rupp, Luise

Institute of Immunology, Faculty of Medicine Carl Gustav Carus, TUD Dresden University of Technology, Dresden, Germany
(P 243) CLINICAL SIGNIFICANCE OF TUMOR-INFILTRATING IMMUNE CELL SUBSETS IN THE RETROPERITONEAL DEDIFFERENTIATED LIPOSARCOMAS AND LEIOMYOSARCOMAS
Luise Rupp
Favorite
Rush, Laura

The Ohio State University
(P 221) QUALITATIVE ANALYSIS OF THE PERIOPERATIVE EXPERIENCE OF YOUNG ADULT PATIENTS UNDERGOING EXTREMITY SARCOMA SURGERY
Laura Rush
Favorite
Ruspi, Laura

IRCCS Humanitas Research Hospital
(P 203) MINIMALLY INVASIVE RESECTION OF MULTIFOCAL DUODENO-JEJUNAL GISTS IN NEUROFIBROMATOSIS TYPE 1
Laura Ruspi
Favorite
(P 318) BURIED DE-EPITHELIALIZED FLAP RECONSTRUCTION AFTER WIDE EXCISION OF THIGH SARCOMAS: EARLY EXPERIENCE FROM A SPECIALIZED SARCOMA SURGERY UNIT
Laura Ruspi
Favorite
(P 339) POSTERIOR APPROACH FOR RADICAL RESECTION OF SACROCOCCYGEAL CHORDOMA: A SURGICAL PERSPECTIVE FROM A TERTIARY REFERRAL CENTER
Laura Ruspi
Favorite
(P 365) UROLOGICAL RECONSTRUCTION DURING RETROPERITONEAL AND PELVIC SARCOMA SURGERY: EXPERIENCE FROM A HIGH-VOLUME SARCOMA CENTER
Laura Ruspi
Favorite
Russo, Luigi

BC Cancer Agency
(P 143) IMPACT OF SURGICAL MARGINS IN CHEST WALL CHONDROSARCOMAS: A CANSARCC STUDY
Luigi Russo
Favorite
(P 395) ERIBULIN IN RECURRENT PRETREATED METASTATIC SOFT TISSUE SARCOMA. A CANADIAN SARCOMA RESEARCH AND CLINICAL COLLABORATION (CANSARCC) REAL WORLD ANALYSIS
Luigi Russo
Favorite
Rutkowski, Piotr

Maria Sklodowska-Curie National Research Institute of Oncology
(P 27) MOLECULAR CHARACTERIZATION OF RESPONSE TO NEOADJUVANT CHEMORADIATION IN PATIENTS WITH LOCALLY ADVANCED SOFT TISSUE SARCOMAS
Piotr Rutkowski
Favorite
(P 134) INTEGRATIVE MICRORNA PROFILING IN CHONDROSARCOMA: TOWARD BIOMARKER DISCOVERY AND PROGNOSTIC SIGNATURE DEVELOPMENT
Piotr Rutkowski
Favorite
(P 139) IMMUNOGENOMIC PROFILING OF CHONDROSARCOMA REVEALS DISTINCT IMMUNE PHENOTYPES AND PROGNOSTIC MUTATIONS
Piotr Rutkowski
Favorite
(P 146) LOCALISED CHONDROSARCOMA PERIOPERATIVE TREATMENT: REAL-WORLD OUTCOMES AND CHALLENGES ACROSS HISTOLOGIC SUBTYPES
Piotr Rutkowski
Favorite
(P 149) SURGICAL TEXTBOOK OUTCOMES IN PATIENTS DIAGNOSED WITH CHONDROSARCOMA
Piotr Rutkowski
Favorite
(P 152) EFFICACY OF PALLIATIVE CHEMOTHERAPY AND LOCAL TREATMENTS IN ADVANCED CHONDROSARCOMA: A SUBTYPE-SPECIFIC RETROSPECTIVE ANALYSIS
Piotr Rutkowski
Favorite
(P 164) LONG TERM OUTCOMES IN PATIENTS DIAGNOSED WITH SECONDARY CHONDROSARCOMA
Piotr Rutkowski
Favorite
(P 191) EFFICACY OF SYSTEMIC PALLIATIVE THERAPIES IN PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMORS (GIST) PREVIOUSLY TREATED WITH ADJUVANT IMATINIB - REAL-WORLD CLINICAL PRACTICE DATA
Piotr Rutkowski
Favorite
(P 216) VIRTUAL MULTIDISCIPLINARY MEETINGS IN THE CARE OF SARCOMA PATIENTS
Piotr Rutkowski
Favorite
(P 313) SIGNIFICANCE OF LYMPH NODE PROCEDURES IN SOFT TISSUE SARCOMA PATIENTS
Piotr Rutkowski
Favorite
(P 407) PIMICOTINIB IN TENOSYNOVIAL GIANT CELL TUMOR (TGCT): LONG-TERM EFFICACY, SAFETY, AND PATIENT-REPORTED OUTCOMES FROM THE PHASE 3 MANEUVER STUDY
Piotr Rutkowski
Favorite
(P 470) OFF-LABEL TREATMENT AND ULTRARARE SARCOMAS - SINGLE INSTITUTION REPORT
Piotr Rutkowski
Favorite
R, VINITH

All India Institute Of Medical Sciences
(P 435) A PHASE II STUDY OF HIGH DOSE IFOSFAMIDE IN METASTATIC/LOCALLY ADVANCED SYNOVIAL SARCOMA FROM A TERTIARY CARE CENTER IN INDIA
VINITH R
Favorite
Ryan, Christopher

OHSU Knight Cancer Institute, South Waterfront
(P 422) EFFICACY WITH VIMSELTINIB IN PATIENTS (PTS) WITH TENOSYNOVIAL GIANT CELL TUMOR (TGCT) AND PRIOR COLONY-STIMULATING FACTOR 1 (CSF1) INHIBITOR THERAPY: A PHASE 2 CASE SERIES
Christopher Ryan
Favorite
Rytlewski, Jeffrey

University of Colorado School of Medicine
(P 234) DOXORUBICIN PLUS BOTENSILIMAB, A NEXT GENERATION CTLA4 INHIBITOR, WITH OR WITHOUT BALSTILIMAB, A PD1 INHIBITOR, IN PATIENTS WITH ADVANCED SOFT TISSUE SARCOMAS
Jeffrey Rytlewski
Favorite
Ryu, Faith

Stanford Medicine
(P 400) LONGITUDINAL EPIGENETIC AND TRANSCRIPTOMIC REMODELING ACROSS PRIMARY, IRRADIATED, AND LOCALLY RELAPSED SOFT TISSUE SARCOMAS
Faith Ryu
Favorite
Ryu, Min-Hee

Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine
(P 194) UPDATED RESULTS FROM STRATEGIST 1: A PHASE 1/1B STUDY OF IDRX-42 (GSK6042981A) IN PATIENTS (PTS) WITH ADVANCED GASTROINTESTINAL STROMAL TUMORS (GIST)
Min-Hee Ryu
Favorite